(-0.35%) 5 049.25 points
(-0.20%) 37 918 points
(-0.59%) 17 467 points
(-1.35%) $80.82
(-2.36%) $1.944
(0.01%) $2 303.20
(0.29%) $26.73
(1.02%) $957.90
(0.01%) $0.937
(-0.04%) $11.09
(0.15%) $0.801
(0.01%) $93.46
@ $1.840
发出时间: 15 Feb 2024 @ 00:29
回报率: -9.24%
上一信号: Feb 13 - 22:30
上一信号:
回报率: -1.60 %
Live Chart Being Loaded With Signals
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...
Stats | |
---|---|
今日成交量 | 91 979.00 |
平均成交量 | 288 616 |
市值 | 32.12M |
EPS | $-0.530 ( 2024-04-04 ) |
下一个收益日期 | ( $-2.03 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.200 |
ATR14 | $0.00600 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Jin David | Buy | 2 352 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-05 | Rosenwald Lindsay A Md | Buy | 50 000 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lu Lucy | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lorenz Kevin | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lobell J Jay | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 22 705 545 | Sell: 91 742 |
音量 相关性
Fortress Biotech Inc 相关性 - 货币/商品
Fortress Biotech Inc 财务报表
Annual | 2023 |
营收: | $84.51M |
毛利润: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2023 |
营收: | $84.51M |
毛利润: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2022 |
营收: | $75.74M |
毛利润: | $44.97M (59.37 %) |
EPS: | $-36.10 |
FY | 2021 |
营收: | $63.13M |
毛利润: | $31.05M (49.18 %) |
EPS: | $-0.800 |
Financial Reports:
No articles found.
Fortress Biotech Inc
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。